tbuckley/cabot-search huggingface dataset:
Production and evaluation of soy-chocolatebeverage drink
Authors: Jayeola, Omueti
Journal: Journal of Clinical Oncology (2011)

An experiment was conducted to produce an aqueous extract of soychoco from cocoa beans with aqueous soybean extract. The experiment was conducted in Cocoa Research Institute of Nigeria CRIN, the product formulations were obtained by two different methods. The first method involved the grinding of roasted cocoa nibs with blanched soybeans and the second method involved mixing of the cocoa powder with blanched and ground soybean paste. The blend for the two methods remains the same with 5, 10, 15 and 20% cocoa nibs or powder addition. The mixture was diluted with water and sieved. The aqueous solution obtained was boiled and sweetened with 10% sugar. The products so produced were subjected to proximate analysis. Sensory evaluation was carried out using a ten-man panelistic approach. A 9-point hedonic scale was used to assess colour, taste, flavour, consistency and overall acceptability. All the samples showed no significant difference at 5% probability level except for colour and flavour. The overall acceptability revealed that the products were acceptable. This experiment indicated that cocoa could be utilized maximally for this novel product.

	 

	Key words: Blanching, blending, beverage, evaluation, drink complement.
USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ
Authors: Hong Zhu, Fangjie Yan, Tao Yuan, Meijia Qian, Tianyi Zhou, Xiaoyang Dai, Ji Cao, Meidan Ying, Xiaowu Dong, Qiaojun He, Bo Yang
Journal: Cancer Research (2020)

Abstract Yes-associated protein (YAP) and its paralog, transcriptional coactivator with PDZ-binding motif (TAZ), play pivotal roles in promoting the progression of hepatocellular carcinoma. However, the regulatory mechanism underpinning aberrant activation of YAP/TAZ in hepatocellular carcinoma remains unclear. In this study, we globally profiled the contribution of deubiquitinating enzymes (DUB) to both transcriptional activity and protein abundance of YAP/TAZ in hepatocellular carcinoma models and identified ubiquitin-specific peptidase 10 (USP10) as a potent YAP/TAZ-activating DUB. Mechanistically, USP10 directly interacted with and stabilized YAP/TAZ by reverting their proteolytic ubiquitination. Depletion of USP10 enhanced polyubiquitination of YAP/TAZ, promoted their proteasomal degradation, and ultimately arrested the proliferation of hepatocellular carcinoma in vitro and in vivo. Expression levels of USP10 positively correlated with the abundance of YAP/TAZ in hepatocellular carcinoma patient samples as well as in N-nitrosodiethylamine (DEN)-induced liver cancer mice models. Collectively, this study establishes the causal link between USP10 and hyperactivated YAP/TAZ in hepatocellular carcinoma cells and provides a rationale for potential therapeutic interventions in the treatment of patients with hepatocellular carcinoma harboring a high level of YAP/TAZ. Significance: These findings identify USP10 as a DUB of YAP/TAZ and its role in hepatocellular carcinoma progression, which may serve as a potential therapeutic target for hepatocellular carcinoma treatment.
Reply
Authors: Dechun Feng, Mingjiang Xu, Bin Gao
Journal: Hepatology (2015)

Potential conflict of interest: Nothing to report. Author names in bold designate shared co‐first authorship. We greatly appreciate the comments raised by Gineste et al. As we mentioned in our article,1 we examined Klebsiella pneumonia infection in interleukin‐6 knockout (Il‐6–/–) mice while exploring the possible mechanisms underlying liver lipocalin‐2 (LCN2) regulation. We measured serum LCN2 levels after K. pneumonia challenge. In agreement with the results from Gineste et al., we obtained comparable serum LCN2 levels in wild‐type and Il‐6–/– mice 12 and 24 hours post–K. pneumonia injection. However, Il‐6–/– mice became very ill and moribund 12 hours post–K. pneumonia challenge, suggesting that Il‐6–/– mice are more susceptible to bacterial infection. These findings are consistent with several previous reports.2 We cannot simply exclude the role of the IL‐6/IL‐6R/signal transducer and activator of transcription 3 (STAT3) signaling in regulating liver LCN2 production based on the data from Il‐6–/– mice because Il‐6–/– mice have much higher bacterial titers and much higher levels of other cytokines in the serum (e.g., IL‐6 family cytokines, IL‐1) than wild‐type mice postinfection, and these cytokines can compensate to induce LCN2 production in hepatocytes. In addition, Gineste et al. used very high doses of lipopolysaccharide (1000 ng/g body weight) and Escherichia coli, which up‐regulated liver Lcn2 messenger RNA by more than 1000‐fold, while in our studies a lower dose of bacteria was used, and hepatic expression of Lcn2 messenger RNA was up‐regulated by less than 50‐fold.1 Thus, it is likely that compensatory elevation of other mediators promotes hepatic Lcn2 messenger RNA up‐regulation in Il−6–/– mice. In our article, we used hepatocyte‐specific IL‐6 receptor knockout mice (IL‐6RHep–/–) in which IL‐6/IL‐6R signaling was only disrupted in hepatocytes, while the effects of IL‐6 on other cell types, especially immune cells, remained intact. We believe that IL‐6RHep–/– mice are more suitable for studying the regulation of LCN2 in the liver by IL‐6. We observed lower LCN2 levels in IL‐6RHep–/– mice 8 and 24 hours after bacterial challenge than those in wild‐type mice; however, similar levels of serum LCN2 levels were observed in IL‐6RHep–/– and wild‐type mice 36 hours after K. pneumonia challenge. This suggests that IL‐6 plays an important role in inducing LCN2 production in hepatocytes at an early stage of bacterial infection and other cytokines (e.g., murine IL‐6 family cytokines and IL‐1) may compensate to induce the production of LCN2 in the absence of the liver IL‐6/IL‐6R signaling pathway at later stages of host defense.
Antiplatelet Medications Protect Against Aortic Dissection and Rupture in Patients With Abdominal Aortic Aneurysms
Authors: Ayman Elbadawi, Mohamed Omer, Gbolahan Ogunbayo, Philip Owens, Doran Mix, Sean P. Lyden, Scott J. Cameron
Journal: Journal of the American College of Cardiology (2020)
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Authors: Raffit Hassan, George R. Blumenschein, Kathleen N. Moore, Alessandro D. Santin, Hedy L. Kindler, John J. Nemunaitis, Shelly M. Seward, Anish Thomas, Stella K. Kim, Prabhu Rajagopalan, Annette O. Walter, Dirk Laurent, Barrett H. Childs, Nenad Sarapa, Cem Elbi, Johanna C. Bendell
Journal: Journal of Clinical Oncology (2020)

This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody-drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients with advanced, metastatic, or recurrent solid tumors known to express the tumor-differentiation antigen mesothelin.This phase I, open-label, multicenter, dose-escalation and dose-expansion study of anetumab ravtansine enrolled 148 adult patients with multiple solid tumor types. Ten dose-escalation cohorts of patients with advanced or metastatic solid tumors (0.15-7.5 mg/kg) received anetumab ravtansine once every 3 weeks, and 6 expansion cohorts of patients with advanced, recurrent ovarian cancer or malignant mesothelioma received anetumab ravtansine at the maximum tolerated dose once every 3 weeks, 1.8 mg/kg once per week, and 2.2 mg/kg once per week.Forty-five patients were enrolled across the 10 dose-escalation cohorts. The maximum tolerated dose of anetumab ravtansine was 6.5 mg/kg once every 3 weeks or 2.2 mg/kg once per week. Thirty-two patients were enrolled in the 6.5 mg/kg once-every-3-weeks, 35 in the 1.8 mg/kg once-per-week, and 36 in the 2.2 mg/kg once-per-week expansion cohorts. The most common drug-related adverse events were fatigue, nausea, diarrhea, anorexia, vomiting, peripheral sensory neuropathy, and keratitis/keratopathy. There were no drug-related deaths. Anetumab ravtansine pharmacokinetics were dose proportional; the average half-life was 5.5 days. Among 148 patients with mesothelioma or ovarian, pancreatic, non-small-cell lung, and breast cancers, 1 had a complete response, 11 had partial responses, and 66 had stable disease. High levels of tumor mesothelin expression were detected in patients with clinical activity.Anetumab ravtansine exhibited a manageable safety and favorable pharmacokinetic profile with encouraging preliminary antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors. The results allowed for the determination of recommended doses, schedules, and patient populations for anetumab ravtansine in phase II studies.
Training and Fit Testing of Health Care Personnel for Reusable Elastomeric Half-Mask Respirators Compared With Disposable N95 Respirators
Authors: Lisa A. Pompeii, Colleen S. Kraft, Erik A. Brownsword, Morgan A. Lane, Elisa Benavides, Janelle Rios, Lewis J. Radonovich
Journal: JAMA (2020)

This study examines the feasibility of rapidly training and fit testing health care workers to use elastomeric half-mask respirators (EHMRs), widely used in construction and manufacturing, as an alternative to N95 respirators during periods of shortage.
A novel method of biopsy for indeterminate pancreaticobiliary strictures: tube-assisted biopsy
Authors: Sung Woo Ko, Sang Soo Lee, Hoonsub So, Jun Seong Hwang, Tae Jun Song, Sung Koo Lee, Myung-Hwan Kim
Journal: Endoscopy (2020)

Abstract Background Single-operator cholangioscopy (SOC) provides an accurate diagnosis of indeterminate pancreaticobiliary strictures. However, the procedure is expensive and can be performed using only limited accessories. Therefore, we devised a novel tube-assisted biopsy (TAB) technique and evaluated its feasibility, diagnostic yield, and safety for indeterminate pancreaticobiliary strictures. Methods The medical records of patients with indeterminate pancreaticobiliary strictures who underwent TAB between September 2018 and July 2019 were reviewed. We assessed the technical success rate, adverse event rate, sensitivity, specificity, and overall accuracy of TAB in differentiating malignant from benign lesions. Results TABs were performed in 16 patients: 12 had biliary strictures; four had pancreatic strictures. The technical success rate was 93.7 % (15/16), and the sensitivity, specificity, and overall accuracy of TAB were 87.5 %, 100 %, and 93.7 %, respectively. No serious adverse events occurred either during or after the procedure in any of the patients. Conclusions TAB has an acceptable accuracy for the diagnosis of indeterminate pancreaticobiliary strictures and may represent a useful diagnostic method in patients where SOC cannot be implemented.
My total hip replacement
Authors: Louise Grant
Journal: British Journal of Sports Medicine (2020)

My mother had a total hip replacement (THR) 20 years ago, at age 50, just after my dad had died of a brain tumour. She would say, ‘at least this hip problem is not life threatening’. After mum’s joint replacement surgery, I saw her live life to the full—including jet-skiing, tandem paragliding! Her replaced hip (the early small-headed Charnley prosthesis) is still doing great. As a young physiotherapist, I wanted to learn all I could to help mum’s hip stand the test of time and that is where my journey started as a hip specialist physiotherapist in the UK.

My first time as a hip patient was in 2011, after 20 years of treating hip patients (figure 1). I had an accident slipping on some ice and badly tore my left hip labral cartilage. I underwent a hip arthroscopy which after 9 months of tailored graded rehabilitation successfully relieved my pain, muscle inhibition and joint stiffness—it gave me my life back.



Figure 1 
Lou Grant, hip chartered physiotherapist.



Having a hip injury and recovering from the hip arthroscopy gave me valuable insight into how having hip pain can affect you physically and mentally, and how addressing both aspects is equally important.1 My experience really helped me understand my patients better; some of my colleagues and patients joked that I had it done as a …
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
Authors: Ching-Yuan Chang, Haesuk Park, Daniel C. Malone, Ching-Yu Wang, Debbie L. Wilson, Yu-Min Yeh, Sascha Van Boemmel-Wegmann, Wei-Hsuan Lo-Ciganic
Journal: JAMA Network Open (2020)

Since 2011, immune checkpoint inhibitors (ICIs) have been effective treatment options for advanced melanoma. Little is known about how risks of immune-related adverse events (irAEs) vary by ICIs.
Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor β-induced protein and improves survival in sepsis
Authors: Wonhwa Lee, Eun Ji Park, Oh Kwang Kwon, Hyelim Kim, Youngbum Yoo, Shin-Woo Kim, Young-Kyo Seo, In-San Kim, Dong Hee Na, Jong-Sup Bae
Journal: Biomaterials (2020)
Abstract 106: Differential Effects of Mild Therapeutic Hypothermia Against Normothermia for Post-Cardiac Arrest Syndrome According to the Severity Scale
Authors: Mitsuaki Nishikimi, Takayuki Ogura, Kazuki Nishida, Taku Iwami
Journal: Circulation (2019)

Introduction: There are few studies on the differential effects of mild therapeutic hypothermia (MTH) according to the risk class in post-cardiac arrest syndrome (PCAS) patients. Objective: The aim of this study was to evaluate the differential effects of MTH against therapeutic normothermia (TN) for PCAS patients according to our risk classification tool (rCAST). Methods: We used data from the out-of-hospital cardiac arrest (OHCA) registry of the Japanese Association for Acute Medicine (JAAM), which is a multi-center, prospective registry of OHCA patients who were transported to critical care medical centers or hospitals with an emergency care department across Japan. We classified eligible PCAS patients treated with MTH or TN on the basis of our rCAST score which was previously developed by us: low severity group (≤5.5), moderate severity group (6-14), and high severity group (≥14.5). The differential effects of MTH vs. TN for their neurological outcome in the 3 severity categories were evaluated by interaction analysis, and the effect of MTH vs. TN in each group was assessed by multivariate logistic regression analysis and propensity score analysis. The good neurological outcome was defined as a Cerebral Performance Categories score ≤2 at 30 days. Results: Among 12,024 OHCA patients in the registry, data of 460 PCAS patients treated by MTH or TN were analyzed (96 patients; the low score, 192; the moderate score, and 172; the high score group). There was a statistically significant interaction effect between MTH/TN and their neurological outcome at 30 days in the 3 categories (p = 0.022). MTH was significantly associated with good neurological outcome at 30 days in PCAS patients of moderate severity group both in the multivariate logistic regression analysis (adjusted odds ratio, 3.09; 95% confidence interval, 1.13-8.49; p = 0.029) and the propensity score analysis (p = 0.030), while it was not in low and high severity group. Conclusions: The effect of MTH in PCAS patients differed according to the severity of PCAS, and MTH was significantly associated with a good neurological outcome as compared to TN in the moderate severity group.
Possible Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Public Bath Center in Huai’an, Jiangsu Province, China
Authors: Chao Luo, Lun Yao, Li Zhang, Mengchu Yao, Xiaofei Chen, Qilong Wang, Hongbing Shen
Journal: JAMA Network Open (2020)

This case series reports a cluster-spreading event in Huai'an, Jiangsu Province, China, in which a patient with coronavirus disease 2019 (COVID-19) may have transmitted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to 8 healthy individuals.
Abstract 18559: Double or Compound Sarcomere Mutations in Hypertrophic Cardiomyopathy is Not Associated With Worsened Outcomes: A Single Center Cohort Study
Authors: Dana Fourey, Ghadeera Almansoori, Melanie Care, Harry Rakowski, Raymond H. Chan
Journal: Circulation (2015)

Background: The presence of two or more pathogenic sarcomere mutations in patients with hypertrophic cardiomyopathy (HCM) has been reported to be associated with early disease onset, particularly marked left ventricular (LV) hypertrophy, and advanced heart failure. Objective: The aim of the study was to clarify the relationship between multiple disease-causing sarcomere mutations and major cardiovascular outcomes in a large HCM cohort. Methods and Results: Between June 1, 1995, and January 2015, 1104 probands with a diagnosis of HCM were routinely referred for systematic sarcomeric mutational screening at a single HCM center. Pathogenic mutations were identified in 273 (25%). Of these patients, 10 (3.6%) were identified with double/compound sarcomere mutations. They were mostly male (70%), presented at an average age of 33±13 years (range, 21-58), with an average maximal wall thickness of 17 mm (range, 13-26). Of the 9 patients who had a cardiac MRI, 8 (88%) had late gadolinium enhancement (LGE), none of which were considered to be extensive (&gt;20% of LV myocardium). Over a mean follow up of 17.4 ±14 years (range, 3-48 years) there were no sudden cardiac death events. Adverse cardiovascular events or severe disease progression occurred in 4 (40%) patients, with an event rate of 3.4 per 100 patient-years follow up including: 2 (20%) with stroke, 3 (30%) with progression to end-stage HCM (EF&lt;50%), and 1 (10%) with progression to New York Heart Association III/IV symptoms. One patient had myectomy for obstructive symptoms, while none required cardiac transplantation. Three (30%) patients had implantable cardioverter-defibrillator (ICD) for primary prevention. However, over a mean follow-up of 6 years (range 1-14 years), no ICD discharges were documented. Conclusion: These observations do not support the hypothesis that double (or compound) mutations confer a gene dosage effect in HCM, nor is it associated with an adverse prognosis. Mutation analysis has proven imprecise in predicting the phenotype or prognosis for patients with HCM, suggesting that genome-wide association studies and gene expression profiling may be needed for better understanding of its utility in the management of HCM patients.
Forging New Strategies in the Cure of Human Oligometastatic Cancer
Authors: Carlo Greco, Zvi Fuks
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Rendezvous technique assisted by anchor device: a new trick for endoscopic treatment of fistulas in the digestive tract
Authors: Victor Abecia, Manuel Alejandro Mahler, Sebastian Duran, Dante Manazzoni, Juan Pizzala, Guido Villa-Gómez Roig, Mariano Marcolongo
Journal: Endoscopy (2020)

A 50-year-old woman with a past history of total abdominal hysterectomy presented with pneumaturia. Barium enema showed a fistulous tract between the vagina and the sigmoid colon. It was not possible to identify the fistulous tract during a colonoscopy; however, the tract of the fistula could be seen by placing a gastroscope into the vagina. Methylene blue was instilled through the tract but the entrance to the tract in the colon was still not clearly identified. A hydrophilic guidewire was therefore passed through the fistula from the vagina to the colon and grasped with a forceps ([Fig. 1]). A colonoscope with an over-the-scope clip (OTSC) mounted onto it was used to grasp the guidewire with an anchor device ([Fig. 2]) and, using a rendezvous technique, we extracted the guidewire from the vaginal side as the colonoscope was advanced up to the colonic orifice of the fistula ([Fig. 3]). Finally, the OTSC clip was released ([Video 1]). Following this procedure, the patient had complete remission of her symptoms.
A new oncolytic<i>V</i><i>accinia</i><i>virus</i>augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery
Authors: Jahangir Ahmed, Louisa S Chard, Ming Yuan, Jiwei Wang, Anwen Howells, Yuenan Li, Haoze Li, Zhongxian Zhang, Shuangshuang Lu, Dongling Gao, Pengju Wang, Yongchao Chu, Chadwan Al Yaghchi, Joel Schwartz, Ghassan Alusi, Nicholas Lemoine, Yaohe Wang
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Local recurrence and remote metastasis are major challenges to overcome in order to improve the survival of patients with cancer after surgery. Oncolytic viruses are a particularly attractive option for prevention of postsurgical disease as they offer a non-toxic treatment option that can directly target residual tumor deposits and beneficially modulate the systemic immune environment that is suppressed post surgery and allows residual disease escape from control. Here, we report that a novel Vaccinia virus (VV), VVΔTKΔN1L (with deletion of both thymidine kinase (TK) and N1L genes) armed with interleukin 12 (IL-12), can prolong postoperative survival when used as a neoadjuvant treatment in different murine and hamster surgical models of cancer. Methods A tumor-targeted replicating VV with deletion of TK gene and N1L gene (VVΔTKΔN1L) was created. This virus was armed rationally with IL-12. The effect of VVΔTKΔN1L and VVΔTKΔN1L-IL12 on modulation of the tumor microenvironment and induction of tumor-specific immunity as well the feasibility and safety as a neoadjuvant agent for preventing recurrence and metastasis after surgery were assessed in several clinically relevant models. Results VVΔTKΔN1L can significantly prolong postoperative survival when used as a neoadjuvant treatment in three different surgery-induced metastatic models of cancer. Efficacy was critically dependent on elevation of circulating natural killer cells that was achieved by virus-induced cytokine production from cells infected with N1L-deleted, but not N1L-intact VV. This effect was further enhanced by arming VVΔTKΔN1L with IL-12, a potent antitumor cytokine. Five daily treatments with VVΔTKΔN1L-IL12 before surgery dramatically improved postsurgical survival. VVΔTKΔN1L armed with human IL-12 completely prevented tumor recurrence in surgical models of head and neck cancer in Syrian hamsters. Conclusions These data provide a proof of concept for translation of the regime into clinical trials. VVΔTKΔN1L-IL12 is a promising agent for use as an adjuvant to surgical treatment of solid tumors.